All News
Potassium Binder Cuts Hyperkalemia Risk in HF Patients on Spironolactone
(MedPage Today) -- CHICAGO -- Treatment with the potassium binder sodium zirconium cyclosilicate (SZC; Lokelma) stabilized potassium levels among patients with heart failure with reduced ejection f
Read MoreWhat It's Like to Win an Ig Nobel; Oxygen Company Too Big to Ban? AI Cuts Care
(MedPage Today) -- Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week.
Read MoreSTAT+: RFK Jr. is exploring a plan to upend Medicare’s physician payments system
The idea would reduce the role played by the American Medical Association in determining how much doctors get paid
Read MoreSacubitril/Valsartan Curbs Cardiotoxicity From Chemotherapy
(MedPage Today) -- CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial.
Read MoreHoliday Gatherings After the Election Don’t Have to Be Contentious
How to avoid a contentious family holiday after the big election.
Read MoreDiane Coleman, 71, Dies; Fiercely Opposed the Right-to-Die Movement
Her fight for disability rights included founding a group called Not Dead Yet, which protested the work of Dr. Jack Kevorkian and others.
Read MoreWhat to know about Dr. Oz, Trump’s pick to head CMS
Today's health news includes Mehmet Oz as Trump's pick to oversee Medicare and Medicaid, rising alcohol deaths, and more.
Read MoreSTAT+: What records? Chinese company refuses to let FDA inspectors review documents or machinery
The FDA maintained that employees refused to provide complete validation reports and production records for a medicine
Read MoreNearly All Vermonters Have Health Insurance, but Care Is Tough To Find
Almost all people have health insurance in Vermont, a state famed for its maple syrup and Ben & Jerry’s ice cream, yet residents pay the nation’s highest insurance premiums for individual cove
Read MoreInvestors tell Silence Therapeutics to shush
Silence Therapeutics presented what seemed like positive data on zerlasiran, its experimental drug for reducing cardiovascular risk. Then, its stock fell 36%.
Read More